Table 1

Baseline characteristics1-150

Variable, unit (range) Strategy I (n=107) Strategy II (n=101) Strategy III (n=105) Dropouts (n=31) Patients who were not randomly assigned (n=52)
Female sex, %6965645281
Rheumatoid factor positive, %6756655569
Age, years
 Mean 565557671-151 55
 10–90 Centiles37–7435–7337–7338–7930–73
Primary end points
Disability score (0–3)
 10–90 Centiles0.5–2.50.1–2.40.3–2.40.4–2.60.1–2.1
Pain score, mm (0–100)
 10–90 Centiles9–863–829–921–961–72
Joint score (0–534)
 10–90 Centiles35–30638–28044–27947–35720–226
ESR, mm/1st h (0–140)
 10–90 Centiles11–869–8814–8814–878–92
Radiological damage (0–448)
 10–90 Centiles0–120–110–130–60–10
Secondary end points
Wellbeing, mm (0–100)
 10–90 Centiles6–906–8212–9212–922–80
Grip strength, kPa (0–120)
 10–90 Centiles4–586–675–581–439–59
Haemoglobin, mmol/l
 10–90 Centiles6.5–9.06.9–9.16.8–9.07.1–9.26.7–9.0
Morning stiffness, min (0–720)
 10–90 Centiles10–3605–1803–3601–2880–162
C reactive protein, mg/l
 10–90 Centiles0–940–850–720–790–70
Platelet count × 109/l
 10–90 Centiles215–503220–482219–483218–436243–522
  • 1-150 Higher values indicate more active disease, with the exception of values for grip strength and haemoglobin.

  • Mean was presented for normal distribution of the variables, and median for a skew distribution. Presented ranges are theoretical ranges.

  • 1-151 Dropouts had a significantly higher age than all other groups (analysis of variance (ANOVA), p = 0.002).

  • Patients who were not randomly assigned differed significantly from all other groups: less disability (ANOVA, p = 0.05) and lower pain score (ANOVA, p = 0.04).